Two separate, identical, double-blind, randomized, placebo-controlled intervention studies were carried out in the south 
Introduction
The cardio-metabolic syndrome (MetS) 9 is a clustering of related metabolic abnormalities, which is predictive of increased risk of cardiovascular disease (CVD) and is associated with low vitamin D status [see review (1) (4) , using a subset of 524 nondiabetic adults .40 y old from the MRC-Ely prospective study, reported that s25(OH)D concentrations at baseline were inversely related with 10-y risk of hyperglycemia, insulin resistance, and MetS. In a prospective cohort study of 3258 patients with acute coronary syndrome, Dobnig et al. (5) reported an independent association of low s25(OH)D with allcause and vascular mortality and significant inverse correlations between s25(OH)D and risk markers for CVD, systemic inflammation, and oxidative stress. We recently observed associations between increased risk of MetS and CVD risk factors and s25 (OH)D concentrations between 40 and 50 nmol/L in 20-to 40-y-old adults and adolescents (6) .
Although experimental studies have shown a mechanistic rationale for a regulatory effect of 1,25-dihydroxyvitamin D on fasting glucose (7, 8) and blood pressure (BP) (9) , data from intervention studies investigating the effect of increasing circulating 25(OH)D on these and other biomarkers of CVD risk are both limited and frequently confounded due to concomitant treatment with calcium and an inadequate consideration of seasonal effects or personal preferences with respect to sun exposure, which makes results difficult to interpret (1) . Vitamin D receptor (VDR) gene polymorphisms, particularly at the Taq I, Fok I, Apa I, and Bsm I sites, are associated with obesity, MetS, type 2 diabetes, and CVD (10) (11) (12) , but the data are inconsistent. Few intervention studies have considered VDR genotype in relation to CVD outcomes. This study investigated the effect of cholecalciferol supplementation at 0, 5, 10, or 15 mg/d (0-600 IU) during wintertime on biomarkers of CVD risk in 2 groups of adults aged 20-40 and .64 y who took part in 2 separate, identical, double-blind, randomized, placebo-controlled intervention studies carried out in the south and north of Ireland (51-558N), 12 mo apart, to estimate vitamin D requirements (13, 14) .
Participants and Methods
Participants. Participants were apparently healthy, white-skinned men and women. There were 245 young adults aged 20-40 y and 225 older adults aged $64 y who were recruited to 2 identical, 2-center, 22-wk vitamin D intervention studies conducted 12 mo apart. The exclusion criteria included consumption of vitamin D-containing supplements for 12 wk prior to study initiation, a sun/ski vacation during the intervention, or use of tanning facilities of any type. Severe medical illness, preexisting CVD (including hypertension, angina, previous stroke, myocardial infarction, by-pass surgery, hypercholesterolemia, hyperglycemia), hypercalcaemia, known intestinal malabsorption syndrome, excessive alcohol use, taking medications known to interfere with vitamin D metabolism, and pregnancy/lactation were also reasons for exclusion. Both the Clinical Research Ethics Committee of the Cork Teaching Hospitals, University College Cork and the Research Ethics Committee of the University of Ulster, Coleraine approved the studies. All participants gave their written consent according to the Helsinki declaration.
Design and conduct of study. These were double-blind, placebocontrolled studies in which young adults or older adults at 2 centers [Cork, Republic of Ireland (latitude 518N) and Coleraine, Northern Ireland (latitude 558N)] were randomized to receive cholecalciferol at doses of 0 (P), 5 (D3-5), 10 (D3-10), or 15 (D3-15) mg daily for 22 wk. Randomization was centralized, computer generated, and stratified by center and sex. The cholecalciferol and placebo capsules were produced by Banner Pharmacaps (The Netherlands) and were identical in appearance and taste. The cholecalciferol content of the capsules was independently confirmed by HPLC (Consultus). We assessed compliance by capsule counting. An a priori decision was made in the current analysis to include only participants who exceeded 85% compliance. Young adults commenced the intervention study between the October 2 and Fig. 1 ). During the intervention phase, participants either made 2 visits to the study center or were met by researchers on 2 occasions at a convenient location at baseline (wk 0) and endpoint (wk 22). At each visit, an overnight fasting blood sample was taken from each participant. Serum and whole blood were immediately stored at 2808C until analysis (13, 14) .
Clinical, dietary, and lifestyle assessments. Anthropometric measures (height, weight, and waist circumference and biceps, triceps, subscapular, and suprailiac skin-fold thickness) and systolic (SBP) and diastolic BP (DBP) were taken using standard operating procedures as previously described (15) . Habitual intake of calcium and vitamin D was estimated via a validated FFQ (15, 16) administered by a research nutritionist and a health and lifestyle questionnaire assessed physical activity, general health, smoking status, and alcohol consumption. Participants were contacted monthly by phone and/or SMS to promote compliance and encourage completion of the study protocol.
Laboratory analysis. ELISA was used to measure s25(OH)D (OCTEIA 25-Hydroxy Vitamin D, Immuno Diagnostic Systems), intact parathyroid hormone (MD Biosciences), fasting insulin concentrations (INS-EASIA, Biosource Europe), high-sensitivity C-reactive protein (DRG Diagnostics), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor metalloproteinase 1 (TIMP-1) (Quantikine, R&D Systems Europe). Serum glucose and total and HDL cholesterol, and TG were analyzed using enzymatic colorimetric assays (Randox Laboratories). TG values were corrected for free glycerol by subtracting 0.11 mmol/L. LDL cholesterol was calculated using the Friedewald formula (17) . The inter-assay variability was avoided by analyzing all samples from an individual in the same run.
DNA extraction and PCR-restriction fragment length polymorphism analysis of the VDR gene. Genomic DNA was extracted from EDTA whole-blood samples using the Wizard Genomic DNA Purification kit (Promega). DNA was amplified by PCR and analyzed for Fok I and Taq I VDR restriction fragment length polymorphisms using a LightCycler (Roche) with adjacent fluorescent hybridization (FRET) probes and primers specifically designed by Tib Molbiol. The primer and probe sequences used to genotype Fok I were: 59-TGGCACTGACTCTGG-CTCT-39 (forward primer); 59-CACAGGTCATAGCATTGAAGTGAA-39 (reverse primer); 59-TTCTTACAGGGACGGAGGCA-FL (terminal fluorescein-labeled sensor probe complementary to mutant allele); and 59-TGGCGGCCAGCACTTCCCTG-PH (anchor probe). The primer and probe sequences used to genotype Taq I were: 59-CGGTCAGCAGTCATA-GAGGG-39 (forward primer); 59-GGTCGGCTAGCTTCTGGATCAT-39 (reverse primer); 59-CGCTGATCGAGGCCATCCA-FL (terminal fluorescein-labeled sensor probe complementary to wild-type allele); and 59-CCGCCTGTCCAACACACTGCAGACGTAC-PH (anchor probe). PCR was performed using LightCycler FastStart DNA Master HybProbe master mix (Roche Diagnostics). Forward and reverse primers as well as sensor and anchor probes were added at levels recommended by the manufacturer. The reaction mix was denatured at 958C for 10 min followed by 45 cycles of denaturation at 958C for 10 s, annealing at 578C for 10 s, and elongation at 728C for 20 s. The program for analytical melting was 958C for 20 s, 408C for 20 s, and then increased to 808C at a 0.28C/s ramp rate. Fluorescence was continuously measured during the slow temperature increase to monitor the dissociation of the fluorescein-labeled detection probes.
Statistical analysis. Based on previously recorded data on CVD biomarkers from our laboratory in 20-to 40-y-old, overweight, adult volunteers (15), we calculated that a sample size of ;50 would give 80% power to detect a 7-mm Hg decrease [similar to the effects observed by Pfeifer et al. (18) ] in SBP (n = 46) and a 10% decrease in serum cholesterol (n = 53) at P , 0.05. Statistical analyses of the data were conducted using PASW for Windows version 20.0 (IBM). The distributions of all variables were tested with Kolmogorov-Smirnov tests. Variables were log-or square root-transformed to achieve near-normal distributions. The 2 age groups were separately analyzed, because these studies were carried out separately. Differences between men and women at baseline were compared using unpaired t tests of log-transformed variables. Differences in the percentages of individuals by VDR genotype were compared using chi-square analysis. Baseline characteristics were compared across treatment groups using ANOVA with Tukey's test for post hoc comparisons. Interactions with sex, center, and genotype at baseline were investigated using ANOVA. Differences postintervention across treatment groups were tested using ANCOVA, including treatment as a fixed factor in the model, as well as sex, center, and Fok I genotype (older adults only). Baseline concentrations of the dependent variable as well as s25(OH)D, intact parathyroid hormone, and waist circumference at baseline were included as covariates. Differences of P , 0.05 were considered significant.
Results
Baseline characteristics of participants. Of the participants recruited for the 2 studies, 233 young adults and 209 older adults returned for the intervention phase free from any severe medical illness or preexisting CVD (Supplemental Fig. 1 ). It is worth noting that the dropout rates were low in both studies (7% in young and 4% in older adults) and in no instance was dropout related to the intervention. There were no adverse events reported in either study. Compliance rates were 94 and 96% in young and older adults, respectively.
Most clinical and biochemical variables differed between sexes (P , 0.05) ( Table 1 ). Several differences (P , 0.05) were also present between the 2 centers. Young adults from Cork had higher s25(OH)D concentrations and lower DBP, serum MMP-9, TIMP-1, TG, and total, HDL, and LDL cholesterol as well as lower ratios of total cholesterol:HDL and LDL:HDL than their Coleraine counterparts. Cork older adults were slightly older, had a larger waist circumference, and higher s25(OH)D, SBP, serum insulin, and HDL cholesterol concentrations than those in Coleraine, whereas DBP and serum concentrations of MMP-9, TIMP-1, LDL cholesterol, and the ratios of total cholesterol: HDL and LDL:HDL were higher in older adults in Coleraine (P , 0.05; data not shown).
Whereas young women had a higher prevalence of the TT and tt genotypes than young men (P = 0.018), there were no significant differences in any biomarkers across the Fok I or Taq I VDR genotypes in young adults. However, in the older adults, DBP and serum concentrations of serum glucose and total and HDL cholesterol differed according to the Fok I VDR genotype as follows: DBP was lower (P = 0. Cholecalciferol supplementation and cardiovascular risk in adults 1521 median s25(OH)D concentrations at baseline than older adults (median, 54.2 vs. 70.4 nmol/L, respectively) ( Fig. 1) . At endpoint, 79, 49, 26, and 8% of young adults in the P, D3-5, D3-10, and D3-15 groups had s25(OH)D concentrations ,50 nmol/L. The corresponding percentages in older adults were 64, 41, 10, and 10% at endpoint in the same intervention groups, respectively. Interestingly, 23 and 34% of young and older adults in the placebo groups had s25(OH)D concentrations ,30 nmol/L at endpoint. There was no significant effect of treatment on any CVD biomarker in either study (Supplemental Tables 1 and 2 ).
Discussion
There is intense interest in vitamin D and its potential association with cardio-metabolic health. We report the outcomes from 2 double-blind, placebo-controlled, randomized, intervention studies with low incremental doses of cholecalciferol on biomarkers of CVD risk in healthy adults aged 20-40 and $64 y. These are among the first intervention data in vitamin D (as a single treatment) and CVD risk markers in a substantial, seasonally controlled, well-characterized group of healthy young and older adults. Cholecalciferol supplementation at doses of 5-15 mg/d, which are within the range of the current dietary recommendations (19) , had no effect on biomarkers of CVD risk in either age group. These 2 studies were primarily designed to estimate the dietary requirement for vitamin D during wintertime and the doses used were chosen to replicate the distribution of habitual dietary intake of vitamin D in adults. This study design enabled us to calculate that ;10 mg/d of cholecalciferol was required to maintain s25(OH)D above the clinical deficiency threshold of 30 nmol/L (19) and ;25 mm/d would keep s25(OH)D above 50 nmol/L during winter in almost all adults at a latitude of 538N (13, 14) . The Institute of Medicine published dietary recommendations for vitamin D and calcium (19) based on skeletal health outcomes, because the committee found that data on health outcomes such as CVD, diabetes, hypertension, and MetS could not reliably or consistently be causally linked due to a lack of randomized controlled trial data. The current report seeks to address some of the knowledge deficits highlighted in the Agency for Healthcare Research and Quality report (20) . To evaluate the outcomes of the intervention on CVD risk markers, it is important to be mindful of the seasonal effect on s25(OH)D values; the current interventions started at the end of summer, when s25(OH)D would be at its annual peak, which means that status in the placebo group would be expected to decrease. In young adults, s25(OH)D decreased in all groups with the exception of the D3-15 group, who maintained s25(OH)D at the end-of-summer concentration, so it was not surprising that biomarkers of CVD risk in 20-40 y olds in particular did not change in response to the cholecalciferol intervention. In older adults, s25(OH)D increased in both the D3-10 and D3-15 groups, but these increases did not effect changes in CVD risk markers in this healthy sample. These data show clear evidence of a lack of effect of cholecalciferol supplementation on CVD risk in healthy adults at doses up to the current RDA for persons ,70 y (19).
Although several cross-sectional studies have shown an association between vitamin D status and glucose/insulin metabolism (4, 8, 21) and there are well-described mechanisms by which vitamin D and glucose metabolism are linked [see reviews (1, 22, 23) ], data from randomized controlled trials are relatively rare and mainly in patients with type 2 diabetes or other underlying disease, overweight, insulin resistant, or vitamin D deficient. Randomized controlled trials with cholecalciferol (as a single treatment) have improved insulin response to glucose in some (24) (25) (26) (27) but not all studies (28, 29) . The doses used were equivalent to daily intakes of 50-200 mg/d (24, 26, 27, 29) , which are much higher than the current study. The stepwise approach we adopted to supplementation, using low doses in healthy adults, is mindful of the variation in the dose-response of s25(OH)D to supplementation (30) . Future investigations should also consider the value of using a step-wise approach and incremental dosing strategy.
Although there was a dearth of information on which to base power calculations, we tried to ensure that the sample size was sufficient to detect main effects of treatment on BP. Elucidation of a potentially important role for vitamin D in the maintenance of healthy BP has been hampered by confounded results from a limited number of intervention studies. In 1990, Orwoll and Oviatt (31) reported no effect of Ca (1000 mg/d) and cholecalciferol (25 mg/d) supplementation for 3 y on BP in 35 adult men aged 30-92 y compared with 30 age-matched controls, but given the age range, this study had insufficient power to detect a difference. Scragg et al. (32) randomized elderly (n = 189; aged 63-76 y) participants to receive a large dose of cholecalciferol (;2500 mg) or a placebo during the winter, but it had no effect on SBP or DBP. The Women's Health Initiative found no effect of 1000 mg Ca + 10 mg cholecalciferol/d on BP in postmenopausal women (33) and while the sample was large (.36,000), participants were unrestricted as to their use of nutritional supplements during the intervention, which casts doubt over the study outcomes. Recent reanalysis of the Women's Health Initiative speculates that taking calcium supplements, with or without vitamin D, may increase the risk of myocardial infarction and stroke (34, 35) ; however, further investigation to detangle the calcium effect from vitamin D is required. Jorde et al. (36) showed that overweight and obese participants who were randomized to receive 500 mg/d calcium plus cholecalciferol (500 or 1000 mg/wk) for 1 y had a slightly higher increase in SBP compared with those who received calcium plus placebo (2.3 vs. 20.1 mm Hg); however, this study was powered to examine the effect on weight loss, not BP. The 2 studies that observed a beneficial effect on BP used UVB treatment (37) or cholecalciferol plus calcium (18) . We observed no effect on BP, but there were a number of differences, other than the intervention, between our study and that of Pfeifer et al. (18) ; the BP concentrations at baseline were much higher in the Pfeifer study compared with ours and the sample was preselected on the basis of having a s25(OH)D ,50 nmol/L, whereas 80% of young adults and 58% of older adults in our study had s25(OH)D .50 nmol/ L at baseline.
We observed no effects on fasting serum concentrations of cholesterol or TG concentration in the current intervention. Although there are several mechanisms by which vitamin D may have a regulatory role in immune function and inflammation (44) and vitamin D deficiency may lead to immune deregulation (45), our results show that high-sensitivity C-reactive protein was not influenced by vitamin D supplementation. Intervention data are conflicted, again mainly due to the recurrent confounding effects of calcium in most supplementation studies (46) (47) (48) . We also measured serum concentrations of MMP-9 and its inhibitor, TIMP-1, which have an important role in extracellular matrix degradation, synthesis, and remodeling (49). Timms et al. (50) supplemented apparently healthy British adults of Bangladeshi origin (n = 41) who had s25(OH)D concentrations ,27.5 nmol/ L over 1 y with 3-monthly i.m. injections of cholecalciferol, which delivered either 1250 mg (;14 mg/d) or 12.5 mg (;0.13 mg/d) and observed dramatic decreases in MMP-9 (66.8%), TIMP-1 (39.8%), and CRP (23.0%) concentrations in the highdose group. To the best of our knowledge, these data have not been replicated and we observed no effect of vitamin D supplementation on MMP-9 or TIMP-1.
We observed lower DBP in older adults who were heterozygous for the Fok I VDR genotype and lower fasting glucose and total and HDL cholesterol for those with the ff genotype, but there were no effects of these differences on the intervention. A recent study (51) reported an association between the T allele of the Fok I genotype, higher s25(OH)D concentrations, and lower plasma rennin activity, which supports the role of the vitamin D-VDR complex as a potential regulator of rennin activity. Chiu et al. (52) reported that the Fok I polymorphism was an independent determinant of insulin sensitivity in healthy Caucasians, where the merged Ff/ff group had lower insulin sensitivity than the FF group. More recently, Filus et al. (53) reported that FF and Ff carriers had higher fasting insulin and a lower HDL concentration than the ff genotypes. TworowskaBardziń ska et al. (54) reported that the Bsm I polymorphism does not predispose to obesity and insulin resistance, but the BB genotype is connected with an unfavorable lipid profile and Oh and Barrett-Connor (11) found associations between polymorphisms of Apa 1 and glucose intolerance and Bsm 1 and insulin resistance in a nondiabetic Caucasian population. To the best of our knowledge, no intervention study with vitamin D and CVD risk outcomes has considered VDR gene polymorphisms in the study design or analysis, probably because of the very large sample sizes required to adequately account for genotype effects.
In summary, we conclude that supplementation with cholecalciferol up to 15 mg/d, which maintained and/or increased s25(OH)D concentration at peak summertime values during winter, had no impact on risk factors for CVD in healthy young and older adults. If there are effects of vitamin D on cardiometabolic health, they will be evident only at higher intakes than the current U.S. RDA (19) . This analysis provides much-needed data to guide studies evaluating the potential effects of vitamin D on CVD risk outcomes using doses designed to substantially increase the s25(OH)D concentration, particularly in vitamin D-deficient individuals or patient subgroups with elevated CVD risk biomarkers.
